MIM
MBX

MetLife Investment Management’s MBX Biosciences MBX Stock Holding History

MetLife Investment Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
18,250
+2,232
+14% +$78K ﹤0.01% 1518
2026
Q1 		$478K Hold
16,018
– – ﹤0.01% 1772
2025
Q4 		$505K Buy
16,018
+5,000
+45% +$121K ﹤0.01% 1785
2025
Q3 		$193K Hold
11,018
– – ﹤0.01% 2339
2025
Q2 		$126K Buy
+11,018
New +$112K ﹤0.01% 2425
2025
Q1 		– Sell
-7,230
Closed -$133K – 2831
2024
Q4 		$133K Buy
+7,230
New +$154K ﹤0.01% 2496

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

MetLife Investment Management's MBX Position: Q2 2026 in Review

MetLife Investment Management increased its MBX Biosciences (MBX) stake by 14% in Q2 2026, buying an estimated $78K and bringing the position to 18,250 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1518.

MetLife Investment Management first reported a position in MBX in Q4 2024 and has held it in 6 quarters since. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • MetLife Investment Management held 18,250 shares of MBX Biosciences worth $1.01M as of Q2 2026.
  • MetLife Investment Management bought 2,232 MBX Biosciences shares in Q2 2026, an estimated $78K.
  • MBX Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1518 holding.
  • MetLife Investment Management first reported a position in MBX Biosciences in Q4 2024 and has held it in 6 quarters since.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.